Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Total Debt (2019 - 2021)

VYNE Therapeutics' Total Debt history spans 3 years, with the latest figure at $33.4 million for Q2 2021.

  • For Q2 2021, Total Debt rose 1.4% year-over-year to $33.4 million; the TTM value through Jun 2021 reached $33.4 million, up 1.4%, while the annual FY2020 figure was $33.2 million, 1.37% up from the prior year.
  • Total Debt reached $33.4 million in Q2 2021 per VYNE's latest filing, roughly flat from $33.3 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $52.5 million in Q1 2020 to a low of $32.7 million in Q4 2019.
  • Average Total Debt over 3 years is $35.8 million, with a median of $33.2 million recorded in 2020.
  • The largest YoY upside for Total Debt was 1.4% in 2021 against a maximum downside of 36.57% in 2021.
  • A 3-year view of Total Debt shows it stood at $32.7 million in 2019, then increased by 1.37% to $33.2 million in 2020, then rose by 0.61% to $33.4 million in 2021.
  • Per Business Quant, the three most recent readings for VYNE's Total Debt are $33.4 million (Q2 2021), $33.3 million (Q1 2021), and $33.2 million (Q4 2020).